OTCMKTS:GNHAF Vifor Pharma (GNHAF) Stock Price, News & Analysis → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Free GNHAF Stock Alerts $181.25 0.00 (0.00%) (As of 10/21/2022) Add Compare Share Share Today's Range$181.25▼$181.2550-Day Range$181.25▼$181.2552-Week Range$174.25▼$183.50VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Vifor Pharma alerts: Email Address Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. About Vifor Pharma Stock (OTCMKTS:GNHAF)Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of August 9, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.Read More GNHAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNHAF Stock News HeadlinesApril 19, 2024 | yahoo.comVifor Pharma offers to rectify anti-competitive behaviour against rivalApril 19, 2024 | msn.comVifor Pharma offers to fix alleged anti-competitive behaviourApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...May 21, 2023 | finance.yahoo.comKapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusMay 10, 2023 | uk.investing.comVifor Pharma AG (VIFNE)December 14, 2022 | financialpost.comCancellation of remaining publicly held registered shares of Vifor Pharma AGDecember 14, 2022 | financialpost.comCancellation of remaining publicly held registered shares of Vifor Pharma AGOctober 20, 2022 | finance.yahoo.comApproval of extension of exemptions from SIX disclosure and publicity obligationsApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...October 16, 2022 | financialpost.comAustralia’s CSL raises annual profit forecast on Swiss acquisitionOctober 12, 2022 | financialpost.comApproval of delisting of Vifor Pharma AG’s registered sharesAugust 22, 2022 | finance.yahoo.comCSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA NephropathyAugust 22, 2022 | finance.yahoo.comVFMCRP announces U.S. Court upholds validity of Velphoro® patentAugust 18, 2022 | markets.businessinsider.comVifor Fresenius : England's NICE Recommends Tavneos For Treatment Of ANCA-associated VasculitisAugust 18, 2022 | finance.yahoo.comTavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)July 13, 2022 | finance.yahoo.comExtension of the postponement of the settlement of Vifor Pharma tender offerFebruary 23, 2022 | morningstar.comAkebia Therapeutics Amends License Agreement with ViforFebruary 23, 2022 | seekingalpha.comAkebia amends license agreement with Vifor for potential launch of kidney drugFebruary 17, 2022 | finance.yahoo.comVifor Pharma reports sustained growth in 2021January 13, 2022 | nasdaq.comVifor Pharma AG Registered Shares (GNHAF)December 27, 2021 | finance.yahoo.comChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA NodDecember 21, 2021 | finance.yahoo.comVifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®December 20, 2021 | nasdaq.comVifor Pharma Settles Patent Litigations Regarding Injectafer - Quick FactsDecember 20, 2021 | finance.yahoo.comVifor Pharma and American Regent announce settlement of Injectafer® patent litigationDecember 16, 2021 | nasdaq.comVifor Pharma Divests Finished Drug Product Manufacturing Business To CordenPharmaDecember 14, 2021 | finance.yahoo.comAustralia’s CSL to Buy Drugmaker Vifor for $11.7 BillionDecember 14, 2021 | financialpost.comAustralia’s CSL to buy Swiss drugmaker Vifor for $11.7 blnSee More Headlines Receive GNHAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vifor Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:GNHAF CUSIPN/A CIKN/A Webwww.viforpharma.com Phone(158) 851-8000FaxN/AEmployees2,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Shah Abbas Hussain B.Sc. (Age 57)BSc (Hons), Chief Exec. Officer Comp: $2.42MMr. Alexandros SigalasActing CFO & Head of IT & Admin.Mr. Frederic ZwahlenHead of Technical OperationsMr. Julien VignotHead of Investor Relations & TreasuryDr. Oliver P. KronenbergGroup Gen. CounselMs. Nathalie PonnierGlobal Head Corp. CommunicationsMr. Michael Puri (Age 53)Chief HR Officer Dr. Christoph Springer (Age 54)Chief Strategy Officer Dr. Thomas KasparHead of Global Quality ManagementDr. Thierry TeilHead of Global Medical AffairsMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors GNHAF Stock Analysis - Frequently Asked Questions How have GNHAF shares performed in 2024? Vifor Pharma's stock was trading at $181.25 at the beginning of the year. Since then, GNHAF shares have increased by 0.0% and is now trading at $181.25. View the best growth stocks for 2024 here. How do I buy shares of Vifor Pharma? Shares of GNHAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNHAF) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vifor Pharma AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.